Patents by Inventor Nabil El Tayar
Nabil El Tayar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7700314Abstract: PEG-IFN-? conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-?, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-?.Type: GrantFiled: February 13, 2007Date of Patent: April 20, 2010Assignee: Merck Serono SAInventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
-
Patent number: 7456201Abstract: The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.Type: GrantFiled: August 19, 2004Date of Patent: November 25, 2008Assignee: Laboratoires Serono SAInventors: Hitesh Shroff, Adulla P. Reddy, Giampiero De Luca, legal representative, Nadia Brugger, Catherine Jorand-Lebrun, Nabil El Tayar
-
Patent number: 7357925Abstract: PEG-IFN-? conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-?, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-?.Type: GrantFiled: August 28, 2003Date of Patent: April 15, 2008Assignee: Laboratoires SeronosaInventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
-
Patent number: 7268210Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: GrantFiled: May 24, 2005Date of Patent: September 11, 2007Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
-
Publication number: 20070141620Abstract: PEG-IFN-? conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-?, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-?.Type: ApplicationFiled: February 13, 2007Publication date: June 21, 2007Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Nabil El-Tayar, Michael Roberts, Milton Harris, Wayne Sawlivich
-
Publication number: 20050222214Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: ApplicationFiled: May 24, 2005Publication date: October 6, 2005Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael Bentley
-
Patent number: 6914121Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: GrantFiled: June 28, 2002Date of Patent: July 5, 2005Assignee: Applied Research Systems Ars Holding N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
-
Patent number: 6914069Abstract: The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.Type: GrantFiled: May 19, 2001Date of Patent: July 5, 2005Assignee: Applied Research Systems ARS Holding N.V.Inventors: Hitesh Shroff, Adulla P. Reddy, Susan A. Kiernan, Nadia Brugger, Catherine Jorand-Lebrun, Nabil El Tayar
-
Publication number: 20050095676Abstract: The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.Type: ApplicationFiled: August 6, 2004Publication date: May 5, 2005Inventors: Nabil El Tayar, Robert Campbell, Christie Kelton, Chaomei He, Susan Kiernan
-
Publication number: 20050069914Abstract: The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.Type: ApplicationFiled: March 25, 2004Publication date: March 31, 2005Inventors: Robert Campbell, Christie Kelton, Chaomei He, Susan Kiernan, Nabil El Tayar
-
Publication number: 20050026985Abstract: The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.Type: ApplicationFiled: August 19, 2004Publication date: February 3, 2005Inventors: Hitesh Shroff, Adulla Reddy, Nabil El Tayar, Nadia Brugger, Catherine Jorand-Lebrun, Giampiero de Luca
-
Publication number: 20040043002Abstract: PEG-IFN-&bgr; conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-&bgr;, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-&bgr;.Type: ApplicationFiled: August 28, 2003Publication date: March 4, 2004Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
-
Publication number: 20040005554Abstract: The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/ BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.Type: ApplicationFiled: August 10, 2001Publication date: January 8, 2004Inventors: Nabil El Tayar, Robert K. Campbell, Chistie A. Kelton, Chaomei He
-
Publication number: 20030219786Abstract: The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.Type: ApplicationFiled: February 6, 2003Publication date: November 27, 2003Applicant: Applied Research Systems ARS Holding N.V.Inventors: Nabil El Tayar, Susan Kiernan, Robert K. Campbell, Christie A. Kelton, Chaomei He
-
Patent number: 6638500Abstract: PEG-IFN-&bgr; conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-&bgr;, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-&bgr;.Type: GrantFiled: October 30, 2000Date of Patent: October 28, 2003Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nabil El-Tayar, Michael J. Roberts, Milton Harris, Wayne Sawlivich
-
Publication number: 20020183257Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: ApplicationFiled: June 28, 2002Publication date: December 5, 2002Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
-
Patent number: 6482925Abstract: The invention concerns a purified polypeptide corresponding to a mutated form of the soluble LAG-3 protein or of one of its fragments comprising the extra-cellular domain D1 and D2.Type: GrantFiled: January 6, 2000Date of Patent: November 19, 2002Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nabil El Tayar, Bertrand Huard, Renato Mastrangeli, Frederic Triebel
-
Publication number: 20020132844Abstract: The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.Type: ApplicationFiled: May 19, 2001Publication date: September 19, 2002Inventors: Hitesh Shroff, Adulla P. Reddy, Nabil El Tayar, Nadia Brugger, Catherine Jorand-Lebrun
-
Patent number: 6433135Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.Type: GrantFiled: October 30, 2000Date of Patent: August 13, 2002Assignee: Applied Research Systems ARS Holding N.V.Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
-
Patent number: 6372207Abstract: The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon &agr;/&bgr; receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.Type: GrantFiled: December 18, 1998Date of Patent: April 16, 2002Assignee: Applied Research Systems ARS Holding N.V.Inventors: Mark Tepper, Mark Cunningham, David Sherris, Nabil El Tayar, Sean McKenna